GASTROESOPHAGEAL JUNCTION CANCER

This study tests whether adding a new experimental drug (HLX22) to standard treatment can help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 550 adults who have not had prior treatment for the…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific protein (CLDN18.2). The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, bile duct, or pancreatic cancer…

This study tests a new drug combination (Enhertu plus chemotherapy, with or without pembrolizumab) against the standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 726 adults who have not received prior…

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can shrink stomach or gastroesophageal junction tumors. About 200 adults who have not had prior treatment for their cancer will receive one of several drug combination…

This study tests a new drug called AZD0901 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). About 572 adults who have already tried at least one prior therapy will be randomly assigned to recei…

This study compares two surgical procedures—removing part or all of the stomach—for people with advanced cancer where the esophagus meets the stomach. About 120 participants will be randomly assigned to one surgery or the other. The goal is to see which approach leads to longer c…

This study tests a new drug combination (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if the combination shrinks tumors and is safe. About 32 par…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This early-phase trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study aims to find the safest dose and check if the com…

This study tests a new drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers that have not responded to prior treatments. The main goals are to find a safe dose and check for side effects, while a…

This early-phase trial tests a new drug called IKS014 in people with advanced HER2-positive solid tumors, including breast, stomach, and gastroesophageal cancers. The drug is designed to deliver a cancer-killing agent directly to HER2-positive tumor cells. The main goals are to f…